Trends of average ocular symptom scores during the post-challenge period. by Oumayma Arbani (21001472)

Subjects:

Cloning of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Average histopathological lesions and scores noted in trachea and lungs of birds during post-infection period. by Oumayma Arbani (21001472)

Subjects:

Mean AIV-H9N2 shedding titer (Log₁₀) in oropharyngeal swabs. by Oumayma Arbani (21001472)

Subjects:

Growth of transgenic <i>D</i>. <i>parva</i> and control after one month. by Lingru Ruan (18995544)

Subjects:

Line chart of MTT absorbance after PRP supplementation. by Rim Kooli (15426816)

Subjects:

Average body weight trends for the four groups during the post-challenge period. by Oumayma Arbani (21001472)

Subjects:

Effect of PRP on spermatozoa ROS production as assessed by the NBT test. by Rim Kooli (15426816)

Subjects:

Amplification of <i>DpAP2</i> full-length cDNA. by Lingru Ruan (18995544)

Subjects:

Verification of transgenic <i>D</i>. <i>parva</i>. by Lingru Ruan (18995544)

Subjects:

Effect of PRP on succinate dehydrogenase activity as assessed by the MTT test. by Rim Kooli (15426816)

Subjects:

Line chart of NBT absorbance after PRP supplementation. by Rim Kooli (15426816)

Subjects:

Concentration of active substances found in pollen, nectar or honey and concentration used in the study. by Agnieszka Murawska (11021928)

Subjects:

Raw data underlying the quantitative results reported in the manuscript. by Lai Jiang (2401513)

Subjects:

Trends of average respiratory symptom scores during the post-challenge period. by Oumayma Arbani (21001472)

Subjects:

Construction of transgenic <i>D</i>. <i>parva</i> overexpressing <i>DpAP2</i> gene. by Lingru Ruan (18995544)

Subjects:

Carotenoid contents of control and transgenic <i>D</i>. <i>parva</i>. by Lingru Ruan (18995544)

Subjects:

Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

“…</p><p>Conclusions</p><p>Implementing multifactorial interventions by a multidisciplinary team improved several clinical manifestations, including HbA1c, SBP, and eGFR, and decreased cardiovascular risk factors despite the decreased diabetes medication use.…”

Age-adjusted incidence rate of gastric cancer over 2000–2019 and in 2020 in the United States, by histologic type. by Armin Aslani (13009188)

Subjects:

Percent change in age-standardized and delay-adjusted incidence rates of gastric cancer from 2019 to 2020, by age, race and sex in the United States, using the November 2022 data s... by Armin Aslani (13009188)

Subjects: